EMJ Dermatology 7 [Suppl 10] . 2019

| View in Fullscreen

In this issue

IL-23 came under the spotlight during this year’s European Academy of Dermatology and Venereology (EADV) Congress in Madrid, Spain, as the subject of a symposium co-chaired by Profs Reich and Warren, and with the latest data from the guselkumab clinical trial programme, reviewed in two separate articles in the latest addition to EMJ Dermatology.